Neurology and Preclinical Neurological Studies - Review Article

Journal of Neural Transmission

, Volume 120, Supplement 1, pp 9-17

First online:

Is there a need to redefine Parkinson’s disease?

  • Philipp MahlknechtAffiliated withDepartment of Neurology, University of Innsbruck
  • , Werner PoeweAffiliated withDepartment of Neurology, University of Innsbruck Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Parkinson’s disease (PD) is classically defined by its cardinal motor features and current clinical diagnostic criteria require the presence of bradykinesia and at least one additional motor symptom out of tremor, rigidity or postural instability. However, converging evidence from clinical, neuropathological, imaging and genetic research suggests initiation of PD-specific pathology prior to appearance of classical motor signs. This is of particular relevance in relation to the development of disease-modifying or neuroprotective therapies which would require intervention at the earliest stages of disease. A key challenge in PD research, therefore, is to better characterize markers for the ‘preclinical’ stages of the illness. Development of PD criteria by combining such markers allowing for an early diagnosis and intervention could pave the way for the design and implementation of future disease modification trials.

Keywords

Parkinson’s disease (PD) Biomarker Early diagnosis Premotor PD Non-motor symptoms Neuroimaging Molecular biomarkers